refractory hypotension in distributive shock research hub

A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors

This study is looking at a new medicine called angiotensin II for very sick children (0-17 years old) who have very low blood pressure due to a serious infection or illness (distributive shock). It aims to see if this medicine can help reduce the need for other strong blood pressure support drugs.